Financial Performance - The company's total revenue for 2023 is expected to be ¥160,475,226.24, representing a year-on-year increase of 2.22%[6] - The net profit attributable to shareholders is projected to be -¥1,904,832.12, a decline of 110.50% compared to the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be -¥7,655,196.17, down 172.27% year-on-year[6] - Basic earnings per share decreased by 105.41% to -¥0.02[7] - Total assets at the end of the reporting period are estimated to be ¥424,434,050.65, a decrease of 2.05% year-on-year[6] - Shareholders' equity attributable to the company is projected to be ¥317,493,445.22, down 11.36% from the previous year[6] - The company's net asset per share decreased by 55.47% to ¥2.85[7] Capital Changes - The company's stock capital increased by 99.00% to ¥111,360,400.00 due to the implementation of the 2022 annual equity distribution[7] Revenue Composition - The decline in profit is primarily attributed to a decrease in the revenue share of high-margin products and an increase in low-margin feed products[7] Strategic Focus - The company is focusing on technological innovation and expanding its marketing efforts to enhance brand image and core competitiveness[6]
大禹生物(871970) - 2023 Q4 - 年度业绩